The Ozempic War is Over: What the Novo Nordisk and Hims & Hers Settlement Means for Your Access to GLP-1s
Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In
A New Dawn for Diabetes: Groundbreaking Drug Offers Triple Benefit – Fat Burning, Blood Sugar Control, and Muscle Preservation
Biomea Fusion Shares Plummet as Major Public Offering Rocks Investor Confidence Despite Positive Diabetes Data
Pioneering Biochemist Svetlana Mojsov Honored with Prestigious Kimberly Prize for Groundbreaking GLP-1 Discovery
Navigating Today's Health Landscape: From Adult Autism to Viral Challenges and Revolutionary Treatments